Structural and Visual Changes in Branch Retinal Vein Occlusion Patients with Retinal Atrophy
Table 2
Characteristics of non-atrophy versus atrophy eyes.
Variables
Nonatrophy (n = 32)
Atrophy (n = 14)
Value
Age (years)
59.41 ± 10.71
58.29 ± 11.38
0.750
Sex (male/female)
19/13
9/5
0.754
Eye (OD/OS)
15/17
5/9
0.482
Hypertension (±)
15/17
5/9
0.482
Diabetes (±)
5/27
1/13
0.756
Duration from onset to 1st IVR (months)
1.00 (2.00)
1.00 (2.00)
0.960
Duration from 1st IVR to complete resolution of MO (months)
10.00 (5.00)
11.00 (3.00)
0.196
Duration from onset to complete resolution of MO (months)
11.00 (3.00)
12.00 (3.00)
0.317
Number of IVR injections before complete resolution of MO
3.00 (2.00)
4.00 (3.00)
0.610
FAZ area (mm2)
0.37 (0.26)
0.38 (0.23)
0.747
FAZ perimeter (mm)
2.51 (0.91)
2.49 (0.70)
0.747
FAZ AI
1.17 (0.15)
1.17 (0.09)
0.738
FD-300-VD (%)
46.22 (7.10)
40.10 (6.53)
<0.001
Quadrantal SVC-VD (%)
36.21 ± 6.47
25.76 ± 4.57
<0.001
Quadrantal DVC-VD (%)
38.95 (11.05)
27.72 (17.23)
0.001
Foveal SVC-VD (%)
12.87 ± 5.72
10.76 ± 4.07
0.219
Foveal DVC-VD (%)
23.09 ± 8.81
19.09 ± 5.03
0.120
Quadrantal superficial RT (μm)
92.69 ± 17.55
69.92 ± 7.13
<0.001
Quadrantal deep RT (μm)
206.77 ± 20.43
172.87 ± 11.49
<0.001
Foveal full RT (μm)
235.58 ± 30.60
216.46 ± 22.25
0.041
Disruption length of EZ
355.50 (567)
605.50 (678)
0.218
VA before treatment
61.00 (10.00)
53.50 (19.00)
0.092
VA with complete resolution of MO
79.00 (11.00)
72.50 (23.00)
0.062
Improved VA
17.84 ± 8.57
15.93 ± 8.41
0.487
Number of IVR injections during 12 months
4.50 (3.00)
4.00 (3.00)
0.958
All values are presented as mean ± SD or median (IQR). MO: macular oedema; FAZ: foveal avascular zone; AI: acircularity index; FD-300-VD: vascular density within a 300 μm wide ring around the foveal avascular zone; SVC: superficial vascular complex; DVC: deep vascular complex; VD: vascular density; RT: retinal thickness; EZ: ellipsoid zone; VA: visual acuity; the minimal-VD quadrantal: quadrantal for short; SD: standard deviation; IQR: interquartile range.
